Aurora Cannabis (ACB) (ACBFF), unlike other cannabis stocks (HMMJ) such as Canopy Growth (CGC) (WEED), Aphria (APHQF), and Cronos Group (CRON), has delivered a negative return so far this year. Aurora Cannabis closed 1% higher on September 11 at 9.09 Canadian dollars. Let’s look at how this compares to its price target below.
First, let’s look at the consensus recommendation for Aurora Cannabis. Overall, the consensus is a “buy” on this stock for the next 12 months. This recommendation remained unchanged from last month. As we see in the above chart, two analysts have a “strong buy” on the stock, which was one more analyst than last month.
However, the number of analysts recommending a “buy” and a “hold” rating remained unchanged month-over-month at one analyst each. In the past year, more and more analysts have become bullish on the stock, as we can see in the above chart.
On September 10, PI Financial raised its price target on Aurora Cannabis from 13 Canadian dollars to 15 Canadian dollars. The overall consensus price target on Aurora Cannabis on September 11 stood at 10.1 Canadian dollars. This price target translates into an upside of 11% if the current price were to converge with the consensus.
Next, we’ll discuss Aphria.